Default company panoramic image
Logo

NanoMedical Systems, Inc.

NMS develops revolutionary nano-based passive and active implantable drug delivery devices for long-term treatment of a variety of diseases.

Company Summary

NMS is transforming drug delivery—providing a new pathway to personalized medicine. Normal drug dosing has ups & downs that lead to side effects, waste and inconvenience. We partner with Pharmas to create new applications of existing drugs, leveraging Moore’s Law to provide continuous long-term dosing. NMS has a strong research pipeline and IP portfolio with expertise in micro/nano materials and fabrication and regulatory compliant development.

Team

  • Default avatar
    Randy Goodall
    Dr.

    President & CEO, Randy Goodall, has 27 years of experience in technology R&D management in measurement physics, software, and semiconductor R&D and business development. During his 14-year career at Sematech, he worked at the local, state, and national levels to start up multiple R&D consortia, focusing on cross-industry innovations based on the leading-edge chip capabilities. He has a BS/PhD from Caltech / Univ of Oregon in physics.

  • Default avatar
    Mauro Ferrari
    Dr.

    Consulting chief scientist, Mauro Ferrari, is a co-founder and board member of NMS and is the inventor of the NMS technology, the father of “Bio MEMS”, and a life-long prolific research scientist. He led the first-ever National Cancer Inst. initiative to build the world’s largest nano life sciences program. Today he is president of The Methodist Hospital Research Institute, where he remains active in research. He has a PhD from UC Berkeley.

  • Default avatar
    Lee Hudson
    Dr.

    Director of Engineering, Lee Hudson, has over 20 years of experience in medical device product development engineering and brings extensive working knowledge of the quality and regulatory environment required for medical device development. Most of his career he has lead the development of Class III implantable devices, e.g., pace makers. He is a professional engineer and has a BS/PhD from Texas A&M in biomedical engineering.

  • Default avatar
    Sharath Hosali
    Dr.

    Manager of Silicon Technology R&D, Sharath Hosali, is responsible for the design and micro-/nano- fabrication of all NMS devices. He has 14 years of experience in leading-edge semiconductor process, equipment, & materials R&D, including both advanced research and commercial product development. He has a BS/PhD from the prestigious India Institute of Technology / Rensselaer University.

  • Default avatar
    David Saathoff

    David Saathoff is acting CFO. He has over 25 years in business investment & corporate operations experience. He was on the Sematech start-up team and is its longest tenured executive, and as CAO he has worked at the highest levels of industry & government to design and established billions of dollars of advanced technology entities in multiple industries. He also has banking experience and studied business at UT Austin and Harvard Business School

  • Default avatar
    Michael Crowley
    Dr.

    Michael Crowley is consulting marketing and pharmaceutical business development manager. He has over 20 years of experience in pharmaceutical technology R&D and applications development. He has extensive contacts throughout the industry. In addition, he serves as a consulting technical expert for formulation of API’s for use in NMS products. He has a BS/PhD from the Univ. of Missouri / UT Austin.

Advisors

  • Default avatar
    Corp: Nick Fox (DuBois) IP: David Parker (Fulbright)
    Lawyer
    Unconfirmed
    Default avatar
    Meg Youngblood (Maxwell Locke & Ritter)
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    RJB, LLC (Rapoport Foundation of the late Bernard Rapoport)
    Unconfirmed
    Default avatar
    Dr. William Cunningham and Herb Kelleher
    Unconfirmed
    Default avatar
    Texas Emerging Technology Fund
    Unconfirmed